Benign breast disease

Obstetrics and Gynecology

Volumn 116, Issue 3, 2010, Pages 747-758

  Pearlman, Mark D ^a   Griffin, Jennifer L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BROMOCRIPTINE; CEFALEXIN; CLINDAMYCIN; COTRIMOXAZOLE; DANAZOL; DICLOXACILLIN; FLUCONAZOLE; GAMMA LINOLENIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRIMROSE OIL; TAMOXIFEN;

ADENOMATOUS POLYP; ANAMNESIS; ARTICLE; BREAST CANCER; BREAST CYST; BREAST DISCHARGE; BREAST DISEASE; BREAST EXAMINATION; BREAST FIBROADENOMA; BREAST HYPERPLASIA; BREAST TUMOR; CANCER RISK; CARCINOMA IN SITU; CYSTOSARCOMA PHYLLOIDES; DIZZINESS; ECHOMAMMOGRAPHY; GALACTORRHEA; HUMAN; LOBULAR CARCINOMA IN SITU; MASTALGIA; MASTITIS; NAUSEA; PATHOLOGY; PRIORITY JOURNAL; SKIN CANDIDIASIS; ADULT; BREAST; CASE REPORT; FEMALE; MIDDLE AGED; REVIEW; RISK FACTOR;

ADULT; BREAST; BREAST DISEASES; FEMALE; HUMANS; MEDICAL HISTORY TAKING; MIDDLE AGED; RISK FACTORS;

EID: 77957277809     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181ee9fc7     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer. J Clin 2009 July 1, 2009;59: 225-49.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Screening and Diagnosis. 2010. Available at: http://www.nccn.org. Accessed July 17, 2010.
3. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins\Gynecology, ACOG Com mittee of Genetics, Society of Gynecologic Oncologist. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957-66.
4. Kelsey JL, Gammon MD,John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
5. Anderson G, Limacher M, Assaf A, Bassford T, Beresford SAA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.JAMA 2004;291: 1701-12.
6. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA 2002;288:321-33.
7. Heiss G, Wallace R, Anderson G, Aragaki A, Beresford SAA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.
8. Breast cancer and hormone replacement therapy: collabora-tive reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
9. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347:1713-27.
10. Marchbanks P, McDonald J, Wilson H, Burnett N, Daling J, Bernstein L, et al. The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 2002;12:213-21.
11. Cauley J, McTiernan A, Rodabough R, LaCroix A, Bauer D, Margolis K, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-7.
12. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 1993;270:338-43.
13. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
14. Breast Cancer Risk Assessment Tool. 2008. Gail Model risk calculator. Available at: http://www.cancer.gov/bcrisktool/. Retrieved March 1, 2010.
15. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
16. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer.JAMA 2006;296:193-201. (Pubitemid 44050373)
17. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms.JAMA 2001;286:2143-51.
18. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC Intake of dairy products, calcium, and vitamin d and risk of breast cancer.J Natl Cancer Inst2002;94:1301-11.
19. Maruti SS, Willett WC, Feskanich D, Rosner B, Colditz GA. A prospective study of age-specific physical activity and premeno-pausal breast cancer. J Natl Cancer Inst 2008;100:728-37.
20. Peters T, Schatzkin A, Gierach G, Moore S, Lacey J, Wareham N, et al. Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2009;18:289-96.
21. Stafford I, Hernandez J, Laibl V, Sheffield J, Roberts S, Wendel G Jr. Community-acquired methicillin-resistant Staph-ylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 2008;112:533-7.
22. Dixon JM, Ravisekar O, Chetty U, Anderson TJ. Periductal mastitis and duct ectasia: different conditions with different aetiologies. Br J Surgery 1996;83:820-2.
23. Ader DN, Shriver CD. Cyclical mastalgia: prevalence and impact in an outpatient breast clinic sample. J Am Coll Surg 1997;185:466-70.
24. Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and manage-ment of breast pain. Mayo Clin Proc 2004;79:353-72.
25. Mansel RE, Dogliotti L. European multicentre trial of bro-mocriptine in cyclical mastalgia. Lancet 1990;335:190-3.
26. Catania S, Zurrida S, Veronesi P, Galimberti V, Bono A, Pluchinotta A. Mondor's disease and breast cancer. Cancer 1992;69:2267-70.
27. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312: 146-51.
28. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
29. Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer 2007;109:180-7.
30. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 2004;100: 238-44.